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The application of pharmacogenomics could meaningfully contribute toward medicines optimization
within primary care. This review identified 13 studies describing eight implementation models utilizing
a multi-gene pharmacogenomic panel within a primary care or community setting. These were small
feasibility studies (n <200). They demonstrated importance and feasibility of pre-test counseling, the role
of the pharmacist, data integration into the electronic medical record and point-of-care clinical decision
support systems (CDSS). Findings were considered alongside existing primary care prescribing practices
and implementation frameworks to demonstrate how issues may be addressed by existing nationalized
healthcare and primary care infrastructure. Development of point-of-care CDSS should be prioritized;
establishing clinical leadership, education programs, defining practitioner roles and responsibilities and
addressing commissioning issues will also be crucial.
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There is robust evidence that pharmacogenomic (PGx) testing has the potential to improve patient outcomes
by improving medication efficacy and preventing adverse drug reactions (ADRs) [1]. Despite overcoming several
barriers to implementation over the last decade, including generation of evidence supporting the clinical utility of
single gene–drug interactions and the development of clinical guidelines, there is currently no consensus on how
PGx should be implemented within primary care in the UK [2–7].
Approximately 90% of NHS activity occurs within the primary care setting, with 300 million consultations
resulting in 1.1 billion prescription items at a cost of £9.2 billion annually. With this prescribing comes the
challenges of ADRs, polypharmacy and medication adherence. Nearly half of individuals over 75 years of age are
prescribed five or more medications, and 50% of medications are not taken as prescribed [8–11]. These constitute
enormous challenges for primary care and there is considerable interest in the potential of PGx testing to address
these and contribute significantly to medicines optimization [12]. Exposure to medicines for which there are PGx
dosing guidelines is common in primary care. 58% of all adult patients, and 89% of those over 70 years of age, are
prescribed one such medicine, with 47% prescribed two or more and 7% prescribed five or more. 19–21% of all
new prescriptions are for medicines where there is a corresponding PGx dosing guideline [13,14].
Primary care is well placed to deliver on the promise of PGx. There is already a robust infrastructure supporting
medicines optimization and prescribing. Primary care practitioners (PCPs) routinely incorporate many determinants
of drug response into their prescribing practice, including hepatic and renal function, co-morbidities and current
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prescribed medication, using clinical decision support systems (CDSS) within primary care IT systems. As such,
solutions for overcoming implementation barriers, absent in other healthcare settings such as hospitals, may already
exist in primary care.
Here, we review existing implementation models for PGx testing within primary care or community settings.
Economic modeling indicates multigene variants are more cost-effective than single gene or variant tests [15,16].
Further increasing polypharmacy in primary care and need for medicine optimization reinforces the value of
multigene variants. Hence, this review will identify key issues and recommendations for implementing multigene
variants panel testing in primary care.
Methods
A structured literature review was performed up to 12 October 2020 to identify studies describing implementation
models utilizing a multigene PGx panel within a primary care or community setting. This includes PGx decision
support and non-PGx prescribing decision support in the primary care setting. The MEDLINE database was
queried via the PubMed search engine using the following Boolean search terms; ((genomic) AND (primary care))
AND (implement*).
1. ((((community)) OR (primary care) AND (pharmacogen*);
2. ((pharmacogen*) AND (primary care)) AND (implement*);
3. (pharmacogen*) AND (primary care) AND (model);
4. (Primary Care) AND (Pharmacogen*);
5. (Pharmacogen*) AND (community);
6. (Medicines optimization) AND (implement*);
7. (Medicines optimization) AND (decision support).
Articles in the English language, research article (review, clinical or observational study) and relating to humans
were included. In the first instance, abstracts were reviewed to determine eligibility and, where necessary, the full
manuscript was reviewed. Where there was uncertainty around eligibility, the papers were discussed between the
authors.
A data collection form extracted key characteristics of the studies, as listed in Table 2. Following extraction,
key themes were collated. The key themes were then mapped against two existing implementation frameworks
(Table 3): IGNITE framework (Implementing GeNomics In PracTicE) and Integrating Primary and Specialist
Healthcare in the UK [17,18].
Results
Following literature search, 753 articles were identified. As indicated in the PRISM flowchart (Figure 1), 688
studies were excluded at title and abstract and 52 excluded at full text review for non-primary care setting, solely
qualitative methodology or describing utilization of single-gene or drug-gene pair testing strategy [19]. A total of
13 studies describing eight implementation models for PGx profiling via panel testing within primary care were
identified and these are summarized in Table 2 [20–32]. No studies describing implementation of other genomic
testing within primary care were identified. In addition two implementation frameworks describing implementation
of genomic medicine and integrating non-genomic healthcare, and an implemented non-PGx Clinical Decision
Support System were identified [17,18,33].
Dressler et al. recruited three PCPs and provided education to support PGx testing within a rural primary
care practice in the USA [20]. Pre-emptive testing was initiated by the PCP for 49 patients who were >65 years
old, had Medicare insurance, and were taking four or more prescription drugs where at least one drug had a
significant drug–gene interaction. Results were returned to the PCP and pharmacist, and a summary comprising
results, concurrent medications and recommendations regarding medication management was formulated by the
pharmacist for use within the PCP consultation. The model was evaluated through pre- and post-testing surveys
for both PCPs and patients, and impact on current medications [20,21].
Dunnenberger et al. implemented a multi-disciplinary clinic comprising clinical geneticist, genetic counselor
and pharmacist in the USA [22]. PCPs that had undergone education referred into the clinic, and pre-emptive
testing offered to 76 patients, there were no exclusions. Patients had pre-test and results appointments at the clinic,
each lasting an hour; the second delivered by pharmacist or clinical geneticist, and supported by a clinical summary
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65 abstracts reviewed
753 articles identified
13 articles underwent full text
review and were included in
review
688 abstracts excluded: outside
primary care or community setting,
not describing pharmacogenomics
panel, not implementation studies
52 abstracts excluded: solely
qualitative research, outside
primary care or community
settings, single drug-gene pair
testing
Figure 1. Study selection process to determine papers describing implementation models for PGx via panel testing
within primary care.
given to the patient in addition to the electronic medical record (EMR). This model was then adjusted to offer
direct access testing: following referral by the PCP, the patient was sent a testing kit comprising swab and on-line
education, and the results sent to the patient and PCP and added to the EMR [23]. The model was evaluated
through post-test semi-structured interview of 15 PCPs [23].
Schwarz et al. used a research pharmacist to identify and recruit 50 patients from one primary care practice in
the USA who were on seven or more medications, or referred by their PCP [25]. Consent and a buccal sample
were obtained by the pharmacist, and pre-emptive testing carried out via a 15-gene panel. Pharmacogenetic data
and patient-specific data were entered into a CDSS then integrated with guidelines to produce a summary and
recommendations. The summary and gene card were sent to the PCP, and the gene card to the patient. Their
approach was termed medication therapy management plus (MTM-Plus) and was evaluated through identification
of drug–gene interactions and up-take of pharmacist recommendations by the PCP.
Haga et al. compared delivery through recruitment by a pharmacist for reactive testing after prescription of a new
targeted medication with on-site support for PCPs, with recruitment by a PCP who can access support by contacting
an on-call pharmacist [26]. The test comprised six genes predicted to affect metabolism of 12 medications; 63 tests
were performed. Results were communicated to patients at PCP discretion supported by drug-specific brochures.
Evaluation was through pre- and post-test surveys of knowledge, attitudes, confidence and perceived value of PGx
testing eight participating PCPs, rates of pharmacist consultation and PGx test utilization [26,27].
Dawes et al. identified patients with one of a list of chronic conditions, and recruited 191 participants oppor-
tunistically from PCPs in Canada [28]. Testing via buccal swab and a panel, comprising 24 variants in seven genes
predicted to affect metabolism of 24 medications was carried out in primary care by PCPs, and the results linked
to a medication-decision support system (MDSS) and presented in a report. The MDSS was condition-linked,
and PGx and biophysical data manually entered into the MDSS and combined with information from Clinical
Pharmacogenetic Implementation Consortium (CPIC) guidelines to make recommendations regarding medication
options and dosage. The report included related drugs and predicted phenotype. Outcomes were measured: ability
to obtain and genotype samples, yield of samples, ability to link results to MDSS and utilization of MDSS.
Papastergiou et al. trained pharmacists in community pharmacies in Canada with medical geneticist support,
recruiting patients on at least one medication from a known drug-gene pair opportunistically for pre-emptive
testing [29]. Testing via buccal swab for variants within ten genes predicted to affect metabolism of over 100
medications was carried out, and a report comprising only PGx data with recommendations based on CPIC
guidelines was issued. Outcomes were rate of drug therapy problems and acceptance rates of recommendations by
physicians.
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Bank et al. recruited patients from primary care in The Netherlands who were issued an incident prescription from
a specified list of medications from known drug-gene pairs, and had had a previous issue of any medication [30].
A cohort of 200 patients out of 1114 identified as eligible were recruited by treating pharmacists, and testing
via buccal swab for variants within a panel of eight genes. A report summarizing genotypes and recommending
clinical action based on Dutch Working Pharmacogenomic Group (DWPG) guidelines was sent to the requesting
pharmacist. The primary outcome was feasibility. Secondary outcomes were frequency of actionable genotypes
(genotype on the basis of which drug prescription should be altered), number of patients with a combination of
actionable genotype in combination with a drug constituting a known drug-gene pair, number of drug-related
interventions and visits to the pharmacy, and drug dose. A side study quantified impact via number of PGx variants
recorded in the EMR and frequency of ‘re-use’ of PGx information [31].
Van der Wouden et al. utilized community pharmacists in the Netherlands who have applied PGx testing
within the PREPARE (PREemptive Pharmacogenomic Testing for Preventing Adverse Drug Reactions) study of
the Ubiquitous Pharmacogenomics Consortium (U-PGx). Pharmacists enrolled patients under their care, with
planned initiation of one of 39 drugs with a DPWG recommendation, and conducted testing via buccal swab for
variants within a panel of 12 genes. Actionable results were sent to the requesting pharmacist who then exercised
discretion in whether or how to use DPWG recommendations, whether to discuss results with the treating GP
and how to report the results to patients. 19 pharmacists who managed at least two actionable PGx results
were recruited: mixed-methods using surveys and semi-structure interviews were utilized. Study aims were first
to investigate shared decision-making, report of results to patients and time allocation, and secondly to identify
remaining implementation barriers and enablers [31].
All articles included were small feasibility studies describing implementation models in clinical settings, ten
in North America and two in the Netherlands. Four US models comprised 49–76 patient samples and 3–15
PCPs across 1–6 primary care practice sites [20–27], two Canadian models sampled 191 patients across six practice
sites, and 100 patients recruited from community pharmacies respectively [28,29]. Two Dutch models sampled
200 patients recruited from primary care centers and recruited 19 pharmacists who applied PGx testing within
their routine primary care, respectively [30–32]. Outcomes primarily sought to prove feasibility of models, providing
measurement of test utilization, clinical action and physician experience and these studies therefore provide useful,
mostly qualitative, data to consider in implementation of PGx within primary care. Table 1 summarizes study
characteristics with respect to year of publication, country, setting, methodology, implementation models and
outcomes.
The literature review did not identify any existing implementation models for genomic testing in primary care.
The IGNITE framework for implementation of genomic medicine interventions in clinical care identifies high
priority criteria within domains, including organizational readiness for implementation, practitioner self-efficacy,
knowledge and beliefs about the intervention, intervention advantage and cost and process issues [17]; these priorities
are mirrored by facilitators of integration of primary and specialist healthcare [18]. Table 2 summarizes these high
priority criteria and facilitators, mapping them against themes identified from the studies describing implementation
models, UK infrastructure as an exemplar of a nationalized healthcare system and potential enablers.
Discussion
Variation in patient populations, eligibility, sample sizes, study design, panel choice and outcome measures mean
direct comparison of studies is challenging; economic evaluation was not included. North American healthcare
models differ significantly from the UK in infrastructure and funding, so there may be limits of generalizability;
the Dutch healthcare model is more comparable to the UK primary healthcare system.
Key influencing factors emerged from the models: pre-test counseling, PGx testing, the role of the pharmacist,
recording of pharmacogenomic data, decision support, clinical outcomes and education.
Pre-test counseling
Consent was taken by a pharmacist or PCP within routine clinical care, a research or community pharmacist, or
medical geneticist or genetic counselor within a genetics clinic, subsequently by sending a link to an on-line video
to patients at home [20,22,23,25,27–30,32]. Of the latter two approaches, patients perceived neither to be of significantly
different value but were more likely to undergo testing if empowered by pre-test knowledge [24,25].
A genetics clinic model lacked scalability; length of clinic appointment, and family and medication history
taking were barriers [22]. Genetic counselors have expertise in disease-based family histories which are detailed and
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Table 2. Summary of results: key barriers and challenges, key enablers and solutions.






Attendance at appointment within clinical
genetics clinic
Family-history taking
Non-prescribing practitioners taking medication
history
Condensed family history limited to 2 questions




PCP attendance at educational sessions
Delivery of educational sessions at multiple
geographical sites
Lack of PCP knowledge
Lack of pharmacist knowledge
Participation in delivering PGx testing in context of study
Pilot phase for implementation
PCPs undergoing PGx testing themselves
On-demand educational material
Education in combination of formats (face-to-face,
on-line)
Addressing specific educational needs (e.g. report
interpretation, counseling)
Creation of ‘champions’
PCP perception of value and utility of PGx testing
[20–23,27,32]
PGx testing Inability to request PGx testing via EMR
Lack of established eligibility criteria
Turnaround times (7–23 days)
Lack of reimbursement for pharmacist time
Cost to patient
Cost to medical insurer
Buccal sample: patient administered at home
PGx testing via buccal samples: PCP or
pharmacist-administered
[20,23,25,27–30,32]
Role of the pharmacist PCP-initiated testing with access of practitioners
to on-call pharmacy support only
Pharmacist-initiated PGx testing
In-house or MDT Pharmacy support
Recording PGx data in EMR
Formulation of summaries
Pharmacist-led medication review / MTM consultation
[20–22,25–27,29–32]
Recording of PGx data Lack of IT infrastructure
Patient concerns re data governance and privacy
Time taken to record PGx data in EMR
Lack of reimbursement for time
Direct integration of PGx data into EMR
Recording of PGx data in EMR by pharmacist
[20,23,25,27,31,32]





Lack of interoperability between EHR and CDSS
Clinical summary comprising PGx data, medications and
recommendations for medication management.
Linkage of PGx data to guidance




ADR: Adverse drug reaction; CDSS: Clinical decision support system; EMR: Electronic medical record; MDSS: Medication-decision support system; MDT: Multi-disciplinary team; MTM:
Medicines therapy management; PCP: Primary care practitioner/GP; PGx: Pharmacogenomic.
Table 2. Summary of results: key barriers and challenges, key enablers and solutions (cont.).





Lack of access by PCP to pharmacist advice
PCP lack of understanding of applicability
Non-integration into clinical workflow
Recommendations made by community pharmacist
Recommendations reviewed within Medication review
or MTM consultation
[20,25,29,30]
Clinical utility (other) Lack of evidence for cost–effectiveness Prevalence of PGx variants
Prevalence of actionable variants (variants with
concurrent prescription of relevant medication)
‘Re-use’ of PGx data in aiding prescribing decisions
Patient autonomy
Improving concordance
Reassurance regarding medication decisions
Explanation of previous medication experiences or ADR
[20,23–25,27–32]
ADR: Adverse drug reaction; CDSS: Clinical decision support system; EMR: Electronic medical record; MDSS: Medication-decision support system; MDT: Multi-disciplinary team; MTM:
Medicines therapy management; PCP: Primary care practitioner/GP; PGx: Pharmacogenomic.
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time consuming, but have limited knowledge of prescribing [22,34]. PGx-relevant family history comprises only
two necessary questions: ‘what medicines can a family member not take because they have caused problems in the
past?’, and ‘what drug allergies do your family members have?’ [22].
Time taken to consent and lack of appropriate reimbursement were significant barriers to adoption in primary
care, for primary care practitioners, community pharmacists and for patients who declined testing [25,30,32]. A
condensed consent process within existing working practices is more likely to be implementable within the time-
constrained primary care setting; development of a framework analogous to existing competency frameworks could
be an enabler [35]. PGx data is arguably more equivalent to non-genetic variables affecting prescribing than to other
genetic tests and therefore demands less information than a disease-based genomic test, for example, regarding
ethical issues such as implications for family members and potential for discrimination [22,34,36–38].
Although there is currently no consensus core elements needed to reach an informed decision about PGx testing
have been proposed: purpose of testing and role of genes in drug response, test risks and benefits, limitations and
alternatives, future benefits and explanation that testing involves analysis of DNA [39]. The lifetime nature of test
results, the changing nature of guidance regarding prescribing recommendations, advice regarding DNA storage
and privacy issues have been specifically suggested for inclusion [40,41].
Practitioner education
Continuing medical education (CME) courses on genetics and PGx are an effective way to introduce new applica-
tions and even increase personal interest, yet practitioner education was identified as a challenge with only a small
number of practitioners attending educational sessions which were a requirement for participation; UK GPs favor
shorter length sessions accessed on-line [20,42–44]. ‘Comprehensive’ community pharmacist training was regarded
as essential; seminar attendance and study involvement of practitioners led to increased confidence offering, in-
terpreting and utilizing PGx testing, but did not translate into a subsequent increase in the number of PGx tests
undertaken [20,27,29].
PCPs are more likely to access information once they see it benefiting daily practice requiring concise, relevant
primary care focused resources in trusted and familiar on-line sites [44–46]. Some barriers to the integration of
genetics services into primary care are present in the context of PGx implemenation including lack of knowledge
and guidelines [47]. Point-of-care tools could raise awareness, provide education and address other barriers; guideline
and protocol development has been identified as a prerequisite on which awareness and effective education can be
built [44,47]. Provider education was identified as an on-going need and is likely to be most successful in a variety
of formats including face-to-face ‘in-services’, case studies and on-line training [23]. Inclusion in UK primary care
curricula is currently limited [48–50].
Feasibility or pilot studies can facilitate a championing model through establishing adoption, raising awareness
and providing healthcare professional participants with additional knowledge [20,32]. Medicine Therapy Manage-
ment (MTM) Plus approach involved a pharmacist with additional PGx expertise providing advice. There is broad
acceptance that clinical champions are crucial to effective healthcare-related implementation, and to sustainability
of clinical innovation [51,52]. There is also a need for specialty-specific clinical leadership to be linked to formal
education programs and systemically harnessed [53]. An American Society of Health-System Pharmacists (ASHP)
position statement advocates pharmacist champions, pharmacists with additional training to provide leadership in
development of process, guidelines and CDSS; the UK Consultant Pharmacist credentialing provides a potential
mechanism [54,55].
Approach to PGx testing
Testing via saliva samples obtained by pharmacists or patients is feasible, with a high (99.5%) rate of genotype
returns [23,25,27–30]. PCPs varied as to whether they thought testing should be reactive (offered at the time of new
prescription) or pre-emptive [21]. Inability to request a test via an EMR, and a lack of established eligibility criteria
were barriers to testing in primary care [21]. Eligibility criteria for testing exist, and nationally-agreed testing criteria
for the UK are currently under development within the National Genomic Test Directory (GTD) through an
electronic test request platform [56].
Of the studies where turnaround times were reported, average times of 11.7, 7, and 23 days were viewed as
a challenge to implementation, although some studies found that turnaround times did not significantly affect
workflow [21,23,25,27,30]. Widespread pre-emptive testing could address this challenge.
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PGx panels costing $102 Canadian, $300 US and $250 US were offered at no cost to the patient [21,25,28]. Cost
to the patient or medical insurer was identified as a potential barrier and reimbursement for pharmacist time was
identified as imperative for implementation [21,25,29,32]. Cost and cost–effectiveness are identified as key priorities for
successful implementation for PGx and genomic medicine interventions, and any intervention spanning primary
and secondary care [17,18].
Role of the pharmacist
Arguably the most striking theme emerging from all the models was the strong support from PCPs for the
involvement of pharmacists. Their varied roles included identification of eligible patients, formulation of summaries
utilizing PGx data alongside other patient data, recording PGx data in the EMR, in utilization of PGx data within
a full MTM consultation, either in primary care or community pharmacy settings [20–32]. Testing supported
via established in-house pharmacists indicated better outcomes than testing via PCP with access to an on-call
pharmacist, although this model may not be deliverable at scale within the US, many PCPs in the UK already
utilize pharmacist support either through community pharmacist provision, in-house or across local networks [27].
96 and 68% of PGx panel results (96 and 68%) were recorded in the community pharmacist and GP EMR
respectively, although this may be because pharmacists were initiating testing [32]. Furthermore, integration of
PGx testing into medication reviews with pharmacist interpretation, within an appropriate pathway including GP
support is feasible and community pharmacists have the confidence, capability, motivation and expertise to lead in
implementation of PGx profiling into clinical practice [21,25,26,29,32]. The role of the pharmacist has been recognized
by professional bodies internationally, in particular in the USA where the majority of pharmacogenomics services
are pharmacist led: the ASHP position statement argues that pharmacists have a fundamental responsibility to
ensure PGx testing is utilized in medicines optimization, echoed in the UK with a call for pharmacist training in
PGx in order to integrate into medicines optimization and medicines review processes [54,57].
Existing guidelines for medicine optimization recommend applying principles of PINCER (pharmacist-led
Information technology intervention) to reduce medication-errors in general practice through identification of
patients at risk of ADR using IT methodology with follow-up pharmacist support, feedback and educational
outreach [58,59]. Pharmacist-led intervention in the form of medication reviews reduces adverse events in the form
of hospital admissions, evidence for effectiveness of a pharmacist-only intervention in reducing medication errors
is conflicting [58,60]. Addition of educational outreach, established working relations with practices and focus on
specific examples resulted in a multi-faceted intervention more likely to be effective than single interventions [58].
Recording of PGx data in the EMR
Integration of genomic information into electronic prescribing systems has been described as crucial, a pre-requisite,
a ‘sine que non’ [27,58,61]. Digitalisation of tools dramatically reduces practitioner time, with lack of or inadequate
information technology (IT) infrastructure and recording of PGx data identified as barriers; ideally data would be
integrated into the EMR directly, either from the laboratory or via a nation-wide EMR sharing structure [21,25,32].
There are limitations to patient-held PGx data; only 25–35% of PGx direct-to-consumer reports are shared with
physicians, and hand-held cards with PGx data and a code linked to on-line guidance were acceptable in providing
clinical decision support in various healthcare settings only where EHR or IT infrastructure was lacking [62,63].
Barriers to use were time, difficulties integrating into routine workflow, data privacy, inability to integrate PGx with
other patient data, and lack of specificity from guidelines and lack of advice regarding alternative medications [64].
Decision support
PGx data must be used in conjunction with other variables affecting prescribing such as body mass index (BMI),
renal and hepatic function, concurrent medications and other medical conditions [65]. A point-of-care electronic
CDSS or Medication Decision Support System (MDSS) integrating PGx data with other patient data and existing
guidelines to make prescribing recommendations represents physician preference and is likely to serve as an
educational resource; CDSS has been identified as feasible and critical to successful implementation of PGx into
routine patient care [26,66,67].
PCPs wanted decision support when receiving and discussing PGx test results; PCPs required support in report
interpretation, preferring clinical summaries which include PGx data, current medications and recommendations
for medication management [23,26,32]. Guidance for utilization of PGx data in prescribing decisions exists, with
concordance between CPIC and DPWG guidelines [66,68]. In addition to CPIC recommendations practitioners
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wanted situational and practical guidance either via a patient-specific summary produced by the practice pharmacy
team or discussion between GPs and pharmacists [23,32]. Time constraints and managing patient expectations were
additional challenges for PCPs [23,32]. A condition-based PGx MDSS in primary care integrating patient data
with PGx data to give medication and dosage recommendations is feasible and accessed regularly, being utilized
236-times for 190 patients over 3 months for 11 of the 15 conditions [28].
PGx CDSS have been shown to reduce hospital admissions caused by ADRs, CDSS developed outside the primary
care setting have been described and utilized, but not comprehensively evaluated [69]. Consideration of an existing
non-PGx CDSS implemented into primary care provides insights into implementation of PGx CDSS. CDSS
have previously been shown to improve practitioner prescribing performance through decreased new prescriptions
for potentially harmful medication but did not affect discontinuation rate of pre-existing medications [75]. The
STOPP-START tool (Screening tool for older people’s potentially inappropriate prescriptions-Screening tool to
alert doctors to right/appropriate treatments) is utilized within medication review and embedded within national
medicines optimization guidance [33,59]. Algorithms run parallel to the EMR, extracting relevant patient data and
recommending clinical actions.
Evidence underpinning STOPP-START implementation shows striking commonality with PGx CDSS. GPs
appreciated that STOPP START allowed systematic review of the patient’s therapy, aiding prescription of required
medications and withdrawal of ‘useless’ drugs and improved effectiveness when compared with a non-digitalized
medication review [33,61]. Linkage with the EMR was regarded as absolutely necessary [73]. CDSS needed to
incorporate medical conditions and age, up-to-date medications, and drug-drug interactions, and should be
accredited by professional organizations [73]. A decisive factor influencing GPs views was relevance and validity
of criteria: they should be evidence-based, up-to-date, comprise risk and benefit of prescribing decisions and be
associated with a decreased risk of adverse events [73]. Information was regarded as ‘useless’ if advised caution, or
did not give novel information. A barrier to use was time taken to discuss changes with patients [73].
Thus other factors impacting on implementation may be generalized to PGx CDSS: challenges to algorithm
construction including achieving consensus, code availability and training regarding appropriate codes were critical
to the STOPP-START algorithm’s success [76,77]. Alerts, either suggesting testing, or post-test, need to be imple-
mented carefully to prevent alert fatigue and avoid liabilities; alert systems have variable effects on prescribing
decisions [69–71]. PCPs are more engaged if alerts are relevant and clinically actionable; tailoring allows time-saving
and avoids alert fatigue [61,72–74]. STOPP-START has been implemented and embedded within national guidance
despite limited evidence of economic and quality of life impact; limited evidence for clinical utility remains a barrier
for implementation of PGx CDSS [2,33,59]. Yet it has been argued that the level of evidence for PGx testing should
be the same non-PGx testing when considering inclusion into guidelines and drug labelling [38].
Evidence of clinical impact
Existing models provide proof of feasibility for PGx implementation in primary care, with observations regarding
clinical outcomes in combination with qualitative evaluation of stakeholder’s perspectives. Further research into
prescribing decisions based on PGx data, clinical utility and cost–effectiveness is required in order to support
scalability.
PGx test results from 90–97% of tested individuals included actionable variants and 24–31% of patients were
on a medication associated with an actionable variant (gene–drug interaction, GDI), consistent with existing
data [13,21,25,27,28,30]. There was variability in rates at which recommendations translated into medication changes:
5% from in-house pharmacist, 63% from community pharmacists, and 90% via a MTM summary were accepted
by PCPs or pharmacists [25,27,29,30]. Barriers were lack of access to PCP by pharmacists, PCP lack of understanding
of applicability and non-integration into workflows [29]. 97% of PGx panel results pre-recorded in the EMR were
re-used at least once, with 33% used for up to four prescriptions in a 2.5 year follow-up [31]. GDI seemingly had
no significant effect on dosages, interventions and visits; these outcomes were secondary end-points [30,31].
Physicians saw value and utility in individualizing treatment, guiding decision-making, increased patient satis-
faction and adherence; only three of eight providers were likely to continue to offer PGx testing with no further
PGx testing offered within 6-month follow-up [27].
Implementation
Nationalised commissioning, service delivery, research and educational infrastructure has the potential to facilitate
implementation; for example in the UK the NHS, Genomics England, Genomics Medicine Service, GLH and
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the Genomic Test Directory provide strategic leadership and a robust model of care through construction of
an evidence-based PGx panel, patient eligibility criteria, and delivery of direct-access testing through accredited
laboratories, while HEE GEP is mandated for education and workforce planning. Table 3 maps the domains and
priorities identified within the two implementation frameworks against key issues identified within this review,
existing infrastructure and potential enablers. The findings are consistent recent qualitative studies which identified
the need for evidence for clinical utility, clear cost–effectiveness and reimbursement mechanisms, clear roles and
responsibilities, clear principles for data sharing and well-developed informatics and CDSS [32,78].
PGx data shows greater similarity to non-genomic data used to inform prescribing decisions than to other
genomic data, with implications for testing, consent and utilization. CDSS are feasible, would allow integration
and alignment into existing clinical workflows and improve practitioner performance. Guidelines aiding prescribing
decisions based on PGx data already exist, and, when used at point-of-care, also provide education. Challenges in
developing CDSS remain, namely developing consensus, use of alerts to maximize PCP engagement, availability
of PGx codes, integration of PGx data into the EMR across all care settings, and with other patient data and
up-to-date guidelines to provide comprehensive prescribing decision support.
Conclusion
Review of existing implementation models provide insights into factors influencing operationalization of PGx
testing into primary care. Delivery of PGx testing in primary care and community settings is feasible, with
evidence for pharmacist-led delivery. A proposed delivery model within a nationalized healthcare system will need
to be feasible within the resource-constrained primary care setting and be adequately commissioned. Evidence for
clinical utility and cost–effectiveness are needed, and evidence for scalability is essential, facilitated by national
research infrastructure with consideration for the level of supporting evidence. Awareness-raising and education
programs built on CDSS, creation of clinical champions with additional expertise, pharmacy leadership with multi-
disciplinary collaborative working and clear definition of roles and responsibilities, and development of clinical
pathways with access to clinical expertise are all likely to support successful implementation.
Future perspective
Harnessing existing nationalized healthcare service and healthcare infrastructure could address key remaining issues
in implementing PGx testing within a primary care setting. In addition development of CDSS and data integration
align with strategic aims of service integration and development of secure and interoperable IT architecture. PGx
data shows similarity to non-genomic data used to inform prescribing decisions, meaning existing primary care
infrastructure and prescribing practices provide a foundation for integration and implementation. This similarity
also has implications for development of consent and testing processes and future evidence base. The expertise
and integral role of the pharmacist within the multi-disciplinary primary care team lends itself naturally to the
growth of pharmacist-led PGx testing and delivery with supporting responsibilities, competencies and accreditation.
CDSS are feasible, would align with current clinical practice, allow integration into clinical workflows, improve
practitioner performance and provide point-of-care education through linkage with relevant guidelines. Challenges
in developing CDSS remain: achieving consensus, use of alerts to maximise PCP engagement, availability of codes
for PGx data and integration of PGx data into the EMR across all care settings, with other patient data and
up-to-date guidelines to provide comprehensive prescribing decision support. Nevertheless implementation of PGx
testing within Primary Care settings is potentially within reach and continues to provide great hope for addressing
the growing challenges of polypharmacy and medicines optimization within a resource-constrained healthcare
system.
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Table 3. Frameworks for implementation of genomic and non-genomic interventions into clinical care: domains
and priorities mapped against implementation issues for PGx and potential enablers.
IGNITE Framework
Domain: High Priority Construct
Integrating Primary and
Specialist Healthcare in the UK
Issues identified for consideration of
implementation of PGx into Primary
Care in the UK











National commissioning and strategic
infrastructure: nationalized state-funded NHS,
NHS Genomic Medicine Service and GLH,
Genomic Test Directory, Health Education
England Genomics Education Program,
National Workforce Steering Groups









and skills, definition of roles and
responsibilities
Championing and expert advice role
of PCPs or pharmacists with
experience in PGx testing
Need for clear infrastructure and
pathway
Define roles and responsibilities
within Primary Care Team:
pharmacists able and motivated to
play a key role in leadership and in
implementation within the Primary
Care setting, with PCP and expert
advice and support
Development of CDSS:
Recognition of CDSS as resource for
awareness and education
PCPs and pharmacists in championing roles
within national strategic and commissioning
structures (NHSE, HEE GEP, RCGP)
PCPs and pharmacists with additional genomic
expertise (e.g. MSc in Genomic Medicine,
Consultant Pharmacist model)
Engagement of national representative bodies
(RCGP, RPS)
Collaboration of PCPs and pharmacists within
these structures to establish pathways, roles
and responsibilities
Establishment of local and regional
championing roles: for PCPs and pharmacists.
British National
FormularyNon-pharmacogenomics
evidence-based CDSS implemented within
routine NHS clinical care
Individuals’ characteristics:
Knowledge and beliefs about the
intervention
Self-efficacy
Education: knowledge and skills
Working together: mechanisms
for collaborative working and
sharing knowledge, access to
expert advice
Belief of PCP and pharmacists that
PGx will be of value
Collaborative working within the
Primary Care Team, specifically
prescribing practitioners and
pharmacists
Knowledge and resources linked to
CDSS and PGx results; with mixed
format CME to support
Existing multi-disciplinary working structures
within Primary Care: pharmacists and PCPs
already and increasingly work closely in
multi-disciplinary structure
National, regional and local championing roles
HEE GEP to support development of





Based on evidence and guidelines
Defined roles and responsibilities
Commissioning arrangements
PGx testing with early evidence for
clinical utility
Identification of eligibility criteria
for testing
Process for requesting PGx testing





National research bodies promoting and
supporting PGx research within Primary care
Genomic Test Directory, Pharmacogenomics
Genomics Clinical Interpretation Partnership
and Pharmacogenomics Testing Working
Group establishing national eligibility criteria







Adequate time for consent, testing,
entry of patient information in EMR
and for giving results and SMR
Appropriate reimbursement
Continued generation of evidence for
cost–effectiveness through research programs
Establish commissioning infrastructure and
accountability, aligning with existing NHS
strategy and national primary care
commissioning arrangements
CDSS: Clinical decision support system; CME: Continuing medical education; GLH: Genomic Laboratory Hub; HEE GEP: Health Education England Genomics Education
Programme; IGNITE: Implementing GeNomics In PracTicE; NGIS: National Genomic Information System; NHS: National Health Service; PCP: Primary care practitioner; RCGP:
Royal College General Practitioners; RPS: Royal Pharmaceutical Society; SMR: Structured medication review.
Data taken from [17,18].
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Table 3. Frameworks for implementation of genomic and non-genomic interventions into clinical care: domains
and priorities mapped against implementation issues for PGx and potential enablers (cont.).
IGNITE Framework
Domain: High Priority Construct
Integrating Primary and
Specialist Healthcare in the UK
Issues identified for consideration of
implementation of PGx into Primary
Care in the UK








Championing and expert advice role
of PCPs or pharmacists with
experience in PGx testing
Establishment of local, regional and national
network of champions
PCPs and pharmacists in existing championing
roles within national infrastructure (NHSE,








Shared guidelines and protocols
Exchange of patient information
on EMR
Working together: mechanisms
for collaborative working and
sharing knowledge, access to
expert advice
Adequate time for consent, testing,
entry of patient information in EMR
and forgiving results and SMR
Appropriate reimbursement
Consensus consent framework for
PGx testing
Pathway for recording patient
information within EMR
CDSS with embedded guidelines,
clinically actionable
recommendations
National commissioning structure: aligning
with SMR
Existing HEE GEP Competency Frameworks
(e.g. consent for genomic testing):
development of PGx-specific competency
frameworks
National IT infrastructure: collaboration
between this and primary care IT providers
Resources and training for all responsible for






Patient characteristics Patient-centered characteristics Time taken and process for consent
CDSS: Clinical decision support system; CME: Continuing medical education; GLH: Genomic Laboratory Hub; HEE GEP: Health Education England Genomics Education
Programme; IGNITE: Implementing GeNomics In PracTicE; NGIS: National Genomic Information System; NHS: National Health Service; PCP: Primary care practitioner; RCGP:
Royal College General Practitioners; RPS: Royal Pharmaceutical Society; SMR: Structured medication review.
Data taken from [17,18].
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